Back to Top Skip to main content

Possible cause for severe eczema has been found

Some patients living with severe eczema – a possible disqualifying factor for military service – have been found to have mutations on a gene called CARD11. Identified as a possible cause for the condition, the discovery can lead to exciting possibilities for advancements, according to the researchers. Some patients living with severe eczema – a possible disqualifying factor for military service – have been found to have mutations on a gene called CARD11. Identified as a possible cause for the condition, the discovery can lead to exciting possibilities for advancements, according to the researchers.

Recommended Content:

Conditions and Treatments | Innovation | Warrior Care

For more than 17 million people in the United States living with severe eczema – a condition that results in dry, itchy rashes and disqualifies many from military service – the mystery behind its cause may be all too familiar. Thanks to researchers at the Uniformed Services University of Health Sciences and National Institutes of Health, certain patients may understand more about their condition.

“Studying these … disorders, especially when we can define the disease based on a single mutation, is incredibly informative because you can learn a lot,” said Andrew Snow, assistant professor in the department of pharmacology and molecular therapeutics at USU, and senior co-author of a study recently published in the journal Nature Genetics.

Researchers at the Uniformed Services University of Health Sciences and National Institutes of Health identified mutations in a gene known as CARD11 as one underlying cause for severe eczema. (U.S. Air Force photo by Senior Airman Ashlin Federick)Researchers at the Uniformed Services University of Health Sciences and National Institutes of Health identified mutations in a gene known as CARD11 as one underlying cause for severe eczema. (U.S. Air Force photo by Senior Airman Ashlin Federick)

In this study, mutations in a gene known as CARD11 were identified as one underlying cause for severe eczema. The discovery led the researchers to ask whether excess glutamine can help correct some of the allergy-related defects in patients’ immune cells. The testing was done with T cells, known as the conductors of the body’s immune response against infections, from one patient in a lab, and the results were promising. Additional work with the NIH to study whether symptoms for patients with similar mutations improve with glutamine supplements – a readily available product in stores – is likely, said Snow.

Severe eczema can run in families, which suggests a genetic cause, said Snow. One by one, Snow and NIH allergist Dr. Joshua Milner received referrals for patients who had mutations in the same gene – totaling eight patients from four different families.

“However, such treatments are not a cure for the cause of the disease, particularly if it’s a genetic cause,” said Snow.

During the study, researchers discovered these CARD11 mutations can prevent T cells  from being able to do their jobs normally. The mutations prevent the cells from taking in enough glutamine, which is needed for T cells to maintain their proper function. This may help explain why some patients with severe eczema have a history of pneumonia, warts, and other types of lung and skin infections, said Snow.

While a mutation in the CARD11 gene is only one possible cause for severe eczema, its discovery can influence new therapies. Current treatments, including over-the-counter and prescription pills or creams, focus on bringing down the inflammation and relieving the itching.

Jeffrey Stinson, a former USU graduate student in Snow’s laboratory, who is currently at the National Institute of Standards and Technology and co-author on the study, said the possibility of having something so easily accessible as a targeted form of treatment would be an incredible achievement for those living with severe eczema and other allergic symptoms.

“This genetic condition is considered rare, but it’s important to acknowledge the impact that findings from small, basic research studies like this can have in the medical field,” said Stinson, stressing that the research would not be possible without the time and participation of the families who volunteer. “Thanks to their dedication, we have new and exciting possibilities for advancement before us.” 

You also may be interested in...

Decision Brief Pediatric Health Care Services

Presentation
8/10/2017

Defense Health Board briefing about Pediatric Health Care Services

Recommended Content:

Conditions and Treatments

Pediatric Care in the Military Health System

Presentation
11/1/2016

Pediatric Care in the Military Health System briefing to the Defense Health Board, Nov. 1, 2016.

Recommended Content:

Access, Cost, Quality, and Safety | Conditions and Treatments

Pediatric Health Care Services

Presentation
11/1/2016

Pediatric Health Care Services briefing to the Defense Health Board, Nov. 1, 2016.

Recommended Content:

Conditions and Treatments

Deployment Health Centers Review

Presentation
8/9/2016

Recommended Content:

Conditions and Treatments | Access, Cost, Quality, and Safety

Joint Trauma System

Presentation
8/9/2016

Recommended Content:

Conditions and Treatments | Research and Innovation

Pediatric Clinical Preventive Services

Presentation
8/9/2016

Recommended Content:

Research and Innovation | Conditions and Treatments

Reconstruction and Restoration of the Genitourinary System after Contemporary Battlefield Urotrauma

Presentation
8/9/2016

Recommended Content:

Conditions and Treatments | Health Readiness

Review of the Defense Health Board’s Combat Trauma Lessons Learned from Military Operations of 2001-2013 Report

Presentation
8/9/2016

The in-depth information and recommendations in the report enable [the Office of the Assistant Secretary of Defense for Health Affairs] to consider approaches to enhance Combat Casualty Care.

Recommended Content:

Conditions and Treatments | Research and Innovation | Health Readiness

Naval Center for Combat and Operational Stress Control

Presentation
2/10/2016

Recommended Content:

Conditions and Treatments | Access, Cost, Quality, and Safety

Perspectives of a Deployed Combat Hospital Commander

Presentation
2/10/2016

Recommended Content:

Access, Cost, Quality, and Safety | Conditions and Treatments

6th Medical Group Overview and Mental Health Suicides PTSD and VA Collaboration

Presentation
11/9/2015

6th Medical Group Overview and Mental Health/Suicides/Post Traumatic Stress Disorder and Veterans Affairs Collaboration

Recommended Content:

Conditions and Treatments

Decision Brief NBH Subcommittee Automated Neuropsychological Assessment Metrics 4 Tasking

Presentation
11/9/2015

Decision Brief: Neurological/Behavioral Health Subcommittee Automated Neuropsychological Assessment Metrics 4 Tasking

Recommended Content:

Conditions and Treatments

Biomedical Innovations for Infectious Diseases and Military Psychiatry and Neuroscience

Presentation
8/20/2015

Recommended Content:

Research and Innovation | Conditions and Treatments

Neurological Behavioral Health Subcommittee Update

Presentation
8/20/2015

Neurological/Behavioral Health Subcommittee Update

Recommended Content:

Conditions and Treatments

USAMRIID Biosafety Biosecurity Biosurety and Ebola Response Support

Presentation
8/20/2015

U.S. Army Medical Research Institute of Infectious Disease Biosafety/Biosecurity/Biosurety and Ebola Response Support

Recommended Content:

Conditions and Treatments
<< < 1 2 3 > >> 
Showing results 1 - 15 Page 1 of 3

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.